Pembrolizumab associated hemophagocytic lymphohistiocytosis

被引：45

作者：

Shah, D. ^{[1
]}

Shrestha, R. ^{[1
]}

Ramlal, R. ^{[1
]}

Hatton, J. ^{[1
]}

Saeed, H. ^{[1
]}

机构：

[1] Univ Kentucky, Hematol & Bone & Marrow Transplantat, Lexington, KY 40506 USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷 / 06期

关键词：

D O I：

10.1093/annonc/mdx113

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1403 / 1403

页数：1

共 5 条

[1]

Ammann S, 2016, EUR J IMMUNOL, V47, P1

[2] Hemophagocytic syndromes - An update [J].

Janka, Gritta E. ;

Lehmberg, Kai .

BLOOD REVIEWS, 2014, 28 (04) :135-142

[3] Hemophagocytic lymphohistiocytosis: pathogenesis and treatment [J].

Janka, Gritta E. ;

Lehmberg, Kai .

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2013, :605-611

[4] Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies [J].

Maude, Shannon L. ;

Barrett, David ;

Teachey, David T. ;

Grupp, Stephan A. .

CANCER JOURNAL, 2014, 20 (02) :119-122

[5] Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies [J].

Naidoo, J. ;

Page, D. B. ;

Li, B. T. ;

Connell, L. C. ;

Schindler, K. ;

Lacouture, M. E. ;

Postow, M. A. ;

Wolchok, J. D. .

ANNALS OF ONCOLOGY, 2015, 26 (12) :2375-2391

← 1 →